US 11,786,508 B2
Use of sublingual dexmedetomidine for the treatment of agitation
Krishnan Nandabalan, New Haven, CT (US); Frank Yocca, New Haven, CT (US); Sameer Sharma, New Haven, CT (US); Harsh Negi, New Delhi (IN); and Deepa Saini, Ghaziabad (IN)
Assigned to BioXcel Therapeutics, Inc., New Haven, CT (US)
Filed by BioXcel Therapeutics, Inc., New Haven, CT (US)
Filed on Nov. 18, 2022, as Appl. No. 17/990,312.
Application 17/990,312 is a continuation of application No. 16/474,882, previously published as PCT/US2017/069030, filed on Dec. 29, 2017.
Claims priority of provisional application 62/542,323, filed on Aug. 8, 2017.
Claims priority of provisional application 62/471,393, filed on Mar. 15, 2017.
Claims priority of provisional application 62/441,164, filed on Dec. 31, 2016.
Prior Publication US 2023/0081503 A1, Mar. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4174 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01)
CPC A61K 31/4174 (2013.01) [A61K 9/006 (2013.01); A61K 9/2027 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01)] 6 Claims
 
1. A method of treating agitation in an agitated subject, said agitated subject having schizophrenia, consisting of administering to the oral mucosa of said agitated subject one or two single dosage administrations of 60 micrograms of dexmedetomidine or a pharmaceutically acceptable salt thereof without also causing significant sedation after the administration, wherein the dexmedetomidine or the pharmaceutically acceptable salt thereof produces an anti-agitation effect in less than about 60 minutes after administration; wherein the agitation is not perioperative agitation; and wherein said dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in a solid, water-soluble dosage form and wherein the dosage form is a film.